What IDEAYA Biosciences’ IDE892 expansion means for MTAP-deleted cancers
IDEAYA advances IDE892 into expansion after reaching target exposure, but clinical response and safety data remain the decisive test.
Pharma & Biotech
Pharma & Biotech
Could Verastem Oncology’s KRAS G12D bet change the pancreatic cancer treatment race?
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Pharma & Biotech
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Pharma & Biotech
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.
Pharma & Biotech
How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment
Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.
Pharma & Biotech
Can Ampligen plus durvalumab finally overcome immunotherapy resistance in metastatic pancreatic cancer
Explore what AIM ImmunoTech’s Ampligen Phase 2 data could change for pancreatic cancer immunotherapy and what risks still remain.
Pharma & Biotech
What Propanc Biopharma’s PRP signals about alternative mechanisms in the crowded pancreatic cancer pipeline
Can PRP’s proenzyme approach change pancreatic cancer treatment strategy? Explore what Propanc Biopharma’s data means for oncology innovation.
Pharma & Biotech
A rare survival signal in pancreatic cancer? Actuate Therapeutics’ elraglusib data at ASCO GI 2026 reignites first-line treatment hopes
Find out how Actuate Therapeutics’ elraglusib Phase 2 data at ASCO GI 2026 could change first-line treatment strategies for metastatic pancreatic cancer.
Pharma & Biotech
Can Senhwa’s CX-5461 finally turn cold tumors hot in immunotherapy’s toughest challenge?
Senhwa Biosciences Inc. and BeOne Medicines have signed a clinical supply agreement to explore a novel drug combination aimed at treating hard-to-reach cancers. The collaboration will test Senhwa’s lead compound Pidnarulex (CX-5461), a G-quadruplex stabilizer, in combination with BeOne’s PD-1 inhibitor tislelizumab. The Phase 1b/2a clinical trial will enroll patients with advanced solid tumors, including